ATI-1

ATI-1: sourced facts only. name: "Mechanistically, ATI-1 appears to target valosin-containing protein (VCP/p97) and disrupt its interaction with the UFM1-specific E3 ligase UFL1." [PMID:42060985]; target: "Mechanistically, ATI-1 appears to target valosin-containing protein (VCP/p97) and disrupt its interaction with the UFM1-specific E3 ligase UFL1." [PMID:42060985]; developer: "Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Laboratory of Neuro-System and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China." [PMID:42060985]; modality: "In this study, we identified ATI-1 as a novel small-molecule inhibitor that selectively blocks the early stages of autophagosome formation." [PMID:42060985]; stage: "Furthermore, ATI-1 demonstrates potent antitumor efficacy in xenograft models with minimal overt toxicity." [PMID:42060985]